Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China flag China · Delayed Price · Currency is CNY
16.80
-0.49 (-2.83%)
Nov 17, 2026, 3:00 PM CST

Aurisco Pharmaceutical Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
436.41792.37769.44545.84391.74444.61
Trading Asset Securities
164.95161.52299.83---
Cash & Short-Term Investments
601.36953.91,069545.84391.74444.61
Cash Growth
-42.22%-10.79%95.89%39.34%-11.89%-21.18%
Accounts Receivable
383.15434.32350.87290.78222.11140.72
Other Receivables
2.724.024.238.313.96.19
Receivables
385.88438.34355.11299.09226.01146.91
Inventory
733.15644.88589.72509.8444.94326.8
Prepaid Expenses
----0.17-
Other Current Assets
26.2119.4832.711.3125.521.48
Total Current Assets
1,7472,0572,0471,3661,088939.8
Property, Plant & Equipment
1,9381,7791,497878.33674.18593.26
Long-Term Investments
377.54166.36133.4779.355.315.3
Other Intangible Assets
157.86160.37161.46121.4122.7140.42
Long-Term Deferred Tax Assets
18.3222.5415.7814.2915.248.56
Long-Term Deferred Charges
34.725.326.9111.37-
Other Long-Term Assets
23.5232.0317.41108.3568.14124.09
Total Assets
4,2654,2223,8772,5752,0351,721

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
352.33297.19297.39242.53102.43128.2
Accrued Expenses
59.74121.56121.6492.8951.9540.89
Short-Term Debt
-20.0220.0240.0430-
Current Portion of Long-Term Debt
25.9517.38--1.3-
Current Portion of Leases
-5.875.645.144.934.06
Current Income Taxes Payable
8.426.022516.6412.858.61
Current Unearned Revenue
3.463.066.622.250.988.96
Other Current Liabilities
26.5629.9655.7481.53117.752.36
Total Current Liabilities
476.44521.06532.04501.02322.17193.08
Long-Term Debt
929.62917.96907.0960.464.22-
Long-Term Leases
17.8115.1215.111.2412.2313.91
Long-Term Unearned Revenue
97.99105.9191.5734.027.694.53
Long-Term Deferred Tax Liabilities
5.454.380.10.284.811.92
Total Liabilities
1,5271,5641,546607.03351.13213.44

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
406.18406.2406.2406.2406.2401
Additional Paid-In Capital
613.86613.96606.5584.93553.36491.73
Retained Earnings
1,6571,5731,241975.92751.49592.71
Treasury Stock
-60.03-55.26-22.86-45.72-57.15-
Comprehensive Income & Other
120.36119.51100.3446.2522.2820.8
Total Common Equity
2,7372,6582,3321,9681,6761,506
Minority Interest
----7.991.75
Shareholders' Equity
2,7372,6582,3321,9681,6841,508
Total Liabilities & Equity
4,2654,2223,8772,5752,0351,721

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
973.38976.34947.85116.8852.6917.97
Net Cash (Debt)
-372.01-22.45121.42428.95339.05426.64
Net Cash Growth
---71.69%26.52%-20.53%-24.37%
Net Cash Per Share
-0.91-0.050.301.050.841.06
Filing Date Shares Outstanding
412.91403.41406.2406.2406.2401
Total Common Shares Outstanding
412.91406.2406.2406.2406.2401
Working Capital
1,2701,5361,515865.02766.19746.72
Book Value Per Share
6.636.545.744.844.133.76
Tangible Book Value
2,5792,4972,1701,8461,5531,466
Tangible Book Value Per Share
6.256.155.344.553.823.66
Buildings
-621.3291.81291.85289.74283.37
Machinery
-1,446735.79640.39587.27485.03
Construction In Progress
-217.39869.74280.6479.9347.83